Tag: Psychedelic Medicine

The US pharmaceutical giant has put $906 million behind a next-generation psychedelic for depression, giving one of the industry’s largest ...

As psychedelic medicine moves towards pharmaceutical development, Incannex is attempting to take synthetic psilocybin through the clinical, regulatory and commercial ...

New Mexico is continuing work on the regulatory framework for a medical psilocybin programme, with proposed rules covering the people, ...

Melbourne-based Entropy Neurodynamics is advancing an intravenous psilocin programme spanning binge eating disorder, depression and other neuropsychiatric conditions, with recent ...

Optimi Health has completed production of a new batch of 5mg naturally derived psilocybin capsules, with the same batch set ...

As psilocybin and MDMA move deeper into psychiatric research and clinical practice, the conversation is shifting from therapeutic promise towards ...

Australian psychedelic medicine company Emyria has brought former US Secretary of Veterans Affairs Dr David Shulkin into its strategy as ...

For much of the past decade, the modern psychedelic renaissance has been accompanied by an unusually powerful media narrative. Drugs ...

For much of the past decade, the psychedelic industry has revolved around companies developing the drugs themselves. Psilocybin, MDMA, LSD ...

Definium Therapeutics has reported a second positive Phase 3 trial of its LSD-based treatment for generalized anxiety disorder, strengthening the ...